fig1

From: Evolving models of care in patients with metabolic dysfunction-associated steatotic liver disease, recognising its population burden and the impact of metabolic dysfunction on incident rates of hepatic and extrahepatic outcomes

Evolving models of care in patients with metabolic dysfunction-associated steatotic liver disease, recognising its population burden and the impact of metabolic dysfunction on incident rates of hepatic and extrahepatic outcomes

Figure 1. Consideration of type and number of metabolic syndrome traits along with hepatic disease severity and genetic susceptibility to inform clinical decision making in patients with MASLD. Figure was made using BioRender (https://BioRender.com/e3uqzr1). T2DM: Type 2 diabetes mellitus; HDL: high-density lipoprotein; TAG: triacylglycerol; CV: cardiovascular; GLP-1: glucagon-like peptide-1; GIP: glucose-dependent insulinotropic polypeptide; MDTs: multidisciplinary teams; HCC: hepatocellular carcinoma; CKD: chronic kidney disease; CVD: cardiovascular disease; MASLD: metabolic dysfunction-associated steatotic liver disease.

fig1

Committee on Publication Ethics

Portico

Committee on Publication Ethics

Portico